Search

Your search keyword '"Adhami M"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Adhami M" Remove constraint Author: "Adhami M"
143 results on '"Adhami M"'

Search Results

1. Cognitive Acceleration in Mathematics Education: Further Evidence of Impact

2. Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)

6. P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH-RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL

11. Hypotension in Posterior Retroperitoneoscopic Versus Transperitoneal Laparoscopic Adrenalectomy.

12. Multiple Target Tracking in Wireless Sensor Networks Based on Sensor Grouping and Hybrid Iterative-Heuristic Optimization.

14. Numerical Modeling Based on Implicit Differential Quadrature Method for Two-Dimensional Groundwater Flow Problems.

16. Forty-eight week efficacy and safety of pegcetacoplan in adult patients with paroxysmal nocturnal hemoglobinuria and suboptimal response to prior eculizumab treatment

17. Less extensive surgery for low-risk papillary thyroid cancers post 2015 American Thyroid Association guidelines in an Australian tertiary centre.

18. Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with Indeterminate Fine-Needle Aspiration Cytology.

23. A comprehensive approach to the study of the housing sector in Iraq with special reference to needs, standards, inputs, density and costs as factors in the analysis of housing problems in Baghdad

25. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis

26. A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

31. Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma.

40. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC)

41. [649] CPG 10101 (ACTILON) IN COMBINATION WITH PEGYLATED INTERFERON AND/OR RIBAVIRIN IN CHRONIC HCV GENOTYPE 1 INFECTED PATIENTS WITH PRIOR RELAPSED RESPONSE: WEEK 48 DATA

42. O.105 Early clinical results with CPG 10101, a new investigational antiviral TRL9 agonist being developed for treatment of subjects chronically infected with hepatitis C virus

49. Haemopoietic centres in the developing angelfish, Pterophyllum scalare (cuvier and valenciennes).

50. CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B®HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study

Catalog

Books, media, physical & digital resources